CorVel (CRVL) 10-Q 4 Nov 21 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2021	Nov. 01, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Trading Symbol	CRVL
Entity Registrant Name	CORVEL CORPORATION
Entity Central Index Key	0000874866
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		17,719,870
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	0-19291
Entity Tax Identification Number	33-0282651
Entity Address, Address Line One	5128 Apache Plume Road
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Fort Worth
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	76109
City Area Code	817
Local Phone Number	390-1416
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, Par Value $0.0001 Per Share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Current Assets
Cash and cash equivalents	$ 131,075,000	$ 139,716,000
Customer deposits	61,061,000	56,497,000
Accounts receivable, net	69,438,000	64,722,000
Prepaid taxes and expenses	10,472,000	8,006,000
Total current assets	272,046,000	268,941,000
Property and equipment, net	70,053,000	70,619,000
Goodwill	36,814,000	36,814,000
Other intangibles, net	1,887,000	2,104,000
Right-of-use asset, net	42,177,000	45,324,000
Deferred tax asset, net	1,288,000	613,000
Other assets	636,000	345,000
TOTAL ASSETS	424,901,000	424,760,000
Current Liabilities
Accounts and taxes payable	13,459,000	13,574,000
Accrued liabilities	149,189,000	148,886,000
Total current liabilities	162,648,000	162,460,000
Long-term lease liabilities	38,458,000	41,898,000
Total liabilities	201,106,000	204,358,000
Commitments and contingencies
Stockholders' Equity
Common stock, $.0001 par value: 120,000,000 shares authorized at September 30, 2021 and March 31, 2021; 54,701,476 shares issued (17,763,576 shares outstanding, net of Treasury shares) and 54,529,642 shares issued (17,876,090 shares outstanding, net of Treasury shares) at September 30, 2021 and March 31, 2021, respectively	3,000	3,000
Paid-in capital	196,174,000	185,941,000
Treasury stock ( shares at September 30, 2021 and 36,653,552 shares at March 31, 2021)	(604,190,000)	(564,435,000)
Retained earnings	631,808,000	598,893,000
Total stockholders' equity	223,795,000	220,402,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 424,901,000	$ 424,760,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Mar. 31, 2021
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	54,701,476	54,529,642
Common stock, shares outstanding	17,763,576	17,876,090
Treasury stock, shares	36,937,900	36,653,552

Consolidated Income Statements

Consolidated Income Statements - Unaudited - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
REVENUES	$ 157,743,000	$ 136,028,000	$ 310,363,000	$ 265,628,000
Cost of revenues	121,082,000	105,525,000	236,489,000	208,616,000
Gross profit	36,661,000	30,503,000	73,874,000	57,012,000
General and administrative expenses	16,658,000	15,560,000	33,303,000	31,145,000
Income before income tax provision	20,003,000	14,943,000	40,571,000	25,867,000
Income tax provision	3,931,000	3,078,000	7,656,000	5,700,000
NET INCOME	$ 16,072,000	$ 11,865,000	$ 32,915,000	$ 20,167,000
Net income per common and common equivalent share
Basic	$ 0.90	$ 0.66	$ 1.84	$ 1.12
Diluted	$ 0.88	$ 0.65	$ 1.81	$ 1.11
Weighted average common and common equivalent shares
Basic	17,841,000	17,937,000	17,869,000	17,960,000
Diluted	18,232,000	18,174,000	18,226,000	18,144,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - Unaudited - USD ($)	Total	Common Stock [Member]	Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]
Beginning balance at Mar. 31, 2020	$ 189,711,000	$ 3,000	$ 168,935,000	$ (531,764,000)	$ 552,537,000
Beginning balance, shares at Mar. 31, 2020		54,254,557		(36,285,591)
Stock issued under employee stock purchase plan	257,000	$ 0	257,000	$ 0	0
Stock issued under employee stock purchase plan, shares		3,173		0
Stock issued under stock option plan, net of shares repurchased	4,472,000	$ 0	4,472,000	$ 0	0
Stock issued under stock option plan, net of shares repurchased, shares		121,162		0
Stock-based compensation expense	2,233,000	$ 0	2,233,000	$ 0	0
Purchase of treasury stock	(14,440,000)	0	0	$ (14,440,000)	0
Purchase of treasury stock, shares				(184,963)
Net income	20,167,000	0	0	$ 0	20,167,000
Ending balance at Sep. 30, 2020	202,400,000	$ 3,000	175,897,000	$ (546,204,000)	572,704,000
Ending balance, shares at Sep. 30, 2020		54,378,892		(36,470,554)
Beginning balance at Jun. 30, 2020	198,092,000	$ 3,000	171,412,000	$ (534,162,000)	560,839,000
Beginning balance, shares at Jun. 30, 2020		54,296,812		(36,320,229)
Stock issued under employee stock purchase plan	257,000	$ 0	257,000	$ 0	0
Stock issued under employee stock purchase plan, shares		3,173		0
Stock issued under stock option plan, net of shares repurchased	2,990,000	$ 0	2,990,000	$ 0	0
Stock issued under stock option plan, net of shares repurchased, shares		78,907		0
Stock-based compensation expense	1,238,000	$ 0	1,238,000	$ 0	0
Purchase of treasury stock	(12,042,000)	0	0	$ (12,042,000)	0
Purchase of treasury stock, shares				(150,325)
Net income	11,865,000	0	0	$ 0	11,865,000
Ending balance at Sep. 30, 2020	202,400,000	$ 3,000	175,897,000	$ (546,204,000)	572,704,000
Ending balance, shares at Sep. 30, 2020		54,378,892		(36,470,554)
Beginning balance at Mar. 31, 2021	220,402,000	$ 3,000	185,941,000	$ (564,435,000)	598,893,000
Beginning balance, shares at Mar. 31, 2021		54,529,642		(36,653,552)
Stock issued under employee stock purchase plan	271,000	$ 0	271,000	$ 0	0
Stock issued under employee stock purchase plan, shares		1,534
Stock issued under stock option plan, net of shares repurchased	7,261,000	$ 0	7,261,000	0	0
Stock issued under stock option plan, net of shares repurchased, shares		170,300
Stock-based compensation expense	2,701,000	$ 0	2,701,000	0	0
Purchase of treasury stock	$ (39,755,000)	0	0	$ (39,755,000)	0
Purchase of treasury stock, shares	(284,348)			(284,348)
Net income	$ 32,915,000	0	0	$ 0	32,915,000
Ending balance at Sep. 30, 2021	223,795,000	$ 3,000	196,174,000	$ (604,190,000)	631,808,000
Ending balance, shares at Sep. 30, 2021		54,701,476		(36,937,900)
Beginning balance at Jun. 30, 2021	229,539,000	$ 3,000	192,431,000	$ (578,631,000)	615,736,000
Beginning balance, shares at Jun. 30, 2021		54,642,752		(36,772,445)
Stock issued under employee stock purchase plan	271,000	$ 0	271,000	$ 0	0
Stock issued under employee stock purchase plan, shares		1,534		0
Stock issued under stock option plan, net of shares repurchased	2,117,000	$ 0	2,117,000	$ 0	0
Stock issued under stock option plan, net of shares repurchased, shares		57,190		0
Stock-based compensation expense	1,355,000	$ 0	1,355,000	$ 0	0
Purchase of treasury stock	$ (25,559,000)	0	0	$ (25,559,000)	0
Purchase of treasury stock, shares	(165,455)			(165,455)
Net income	$ 16,072,000	0	0	$ 0	16,072,000
Ending balance at Sep. 30, 2021	$ 223,795,000	$ 3,000	$ 196,174,000	$ (604,190,000)	$ 631,808,000
Ending balance, shares at Sep. 30, 2021		54,701,476		(36,937,900)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - Unaudited - USD ($)	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows from Operating Activities
NET INCOME	$ 32,915,000	$ 20,167,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	11,845,000	11,643,000
(Gain) loss on write down or disposal of property, capitalized software or investment	(11,000)	496,000
Stock compensation expense	2,701,000	2,233,000
Provision for doubtful accounts	129,000	1,498,000
Deferred income tax	(675,000)	(559,000)
Changes in operating assets and liabilities
Accounts receivable	(4,846,000)	(8,826,000)
Customer deposits	(4,563,000)	(3,579,000)
Prepaid taxes and expenses	(2,464,000)	449,000
Other assets	(292,000)	196,000
Accounts and taxes payable	450,000	(3,619,000)
Accrued liabilities	302,000	18,442,000
Operating lease liabilities	(292,000)	966,000
Net cash provided by operating activities	35,199,000	39,507,000
Cash Flows from Investing Activities
Purchase of property and equipment	(11,617,000)	(6,937,000)
Net cash used in investing activities	(11,617,000)	(6,937,000)
Cash Flows from Financing Activities
Purchase of treasury stock	(39,755,000)	(14,440,000)
Exercise of common stock options	7,261,000	4,472,000
Purchases under employee stock purchase plan	271,000	257,000
Net cash used in financing activities	(32,223,000)	(9,711,000)
(Decrease)/increase in cash and cash equivalents	(8,641,000)	22,859,000
Cash and cash equivalents at beginning of period	139,716,000	83,223,000
Cash and cash equivalents at end of period	131,075,000	106,082,000
Supplemental Cash Flow Information:
Income taxes paid	$ 12,534,000	$ 6,235,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 1 — Summary of Significant Accounting Policies Basis of Presentation: The unaudited consolidated financial statements include the accounts of CorVel Corporation and its subsidiaries. Significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements herein have been prepared by CorVel Corporation (“the Company”, “we”, “our”, “us”) pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The accompanying interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the latest fiscal year ended March 31, 2021. Accordingly, note disclosures which would substantially duplicate the disclosures contained in the March 31, 2021 audited consolidated financial statements have been omitted from these interim unaudited consolidated financial statements. The Company evaluated all subsequent events and transactions through the date of filing this report. Certain information and note disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three and six months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2022. For further information, refer to the audited consolidated financial statements and notes thereto for the fiscal year ended March 31, 2021 included in the Company's Annual Report on Form 10-K filed with the SEC on May 28, 2021 . Impact of COVID-19: T he COVID-19 pandemic has impacted and could further impact our operations and the operations of our customers, suppliers and vendors as a result of quarantines, facility closures, illnesses, reduced medical services, and travel and logistics restrictions. The extent to which the COVID-19 pandemic impacts our business, results of operations, and financial condition will depend on future developments, which are highly uncertain and cannot be predicted. This includes, but is not limited to the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on our customers, suppliers, and vendors, the remedial actions and stimulus measures adopted by federal, state, and local governments, the effects of stay at home mandates, the distribution and effectiveness of vaccines, and to what extent normal economic and operating conditions can resume. Even after the COVID-19 pandemic has subsided, we may continue to experience adverse impacts to our business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, Management cannot reasonably estimate the full impact at this time, however, the Company feels the impact has decreased over time. Recent Accounting Pronouncements: Management has evaluated recent accounting pronouncements through the date the financial statements were issued and filed with the Securities and Exchange Commission and believe that there are none that will have a material impact on the Company’s financial statements.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Sep. 30, 2021
Revenue Recognition [Abstract]
Revenue Recognition	Revenue from Contracts with Customers Revenue is recognized when control of the promised services is transferred to the Company’s customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. As the Company completes its performance obligations, which are identified below, it has an unconditional right to consideration as outlined in the Company’s contracts. Generally, the Company’s accounts receivable are expected to be collected in 30 days in accordance with the underlying payment terms. The Company generates revenue through its patient management and network solutions service lines. The Company operates in one reportable operating segment, managed care. Patient Management Service Line The patient management service line provides services primarily related to workers’ compensation claims management and case management. This service line also includes additional services such as accident and health claims programs. Each claim referred by the customer is considered an additional optional purchase of claims management services under the agreement with the customer. The transaction price is readily available from the contract and is fixed for each service. Revenue is recognized over time as services are provided as the performance obligations are satisfied through the effort expended to research, investigate, evaluate, document, and report the claim and control of these services is transferred to the customer. Revenue is recognized based on historical claim closure rates and claim type applied utilizing a portfolio approach based on time elapsed for these claims, generally between three and fifteen months . The Company believes this approach reasonably reflects the transfer of the claims management services to its customers. The Company’s obligation to manage claims and cases under the patient management service line can range from less than one year to multi-year contracts. They are generally one year under the terms of the contract; however, many of these contracts contain auto-renewal provisions and the Company’s customer relationships can span multiple years. Under certain claims management agreements, the Company receives consideration from a customer at contract inception prior to transferring services to the customer, however, the Company would begin performing services immediately. The period between a customer’s payment of consideration and the completion of the promised services is generally less than one year. There is no difference between the amount of promised consideration and the cash selling price of the promised services. The fee is billed upfront by the Company in order to provide customers with simplified and predictable ways of purchasing the Company’s services. The patient management service line also offers the services of case managers who provide administration services by proactively managing medical treatment for claimants while facilitating an understanding of and participation in their rehabilitation process. Revenue for case management services is recognized over time as the performance obligations are satisfied through the effort expended to manage the medical treatment for claimants and control of these services is transferred to the customer. Case management services are generally billed based on time incurred, are considered variable consideration, and revenue is recognized at the amount in which the Company has the right to invoice for services performed. The Company believes this approach reasonably reflects the transfer of the case management service to the customer. Network Solutions Service Line The network solutions service line consists primarily of medical bill review and third-party services. Medical bill review services provide an analysis of medical charges for customers’ claims to identify opportunities for savings. Medical bill review services revenues are recognized at a point in time when control of the service is transferred to the customer. Revenue is recognized based upon the transfer of the results of the medical bill review service to the customer as this is the most accurate depiction of the transfer of the service to the customer. Medical bill review revenues are variable and generally based on performance metrics set forth in the underlying contracts. Each period, the Company bases its estimates on a contract-by-contract basis. The Company makes its best estimate of amounts the Company has earned and expects to be collected using historical averages and other factors to project such revenues. Variable consideration is recognized when the Company concludes that it is probable that a significant revenue reversal will not occur in future periods. Third-party services revenue includes pharmacy, directed care services and other services, and includes amounts received from customers compensating the Company for certain third-party costs associated with providing its integrated network solutions services. The Company is considered the principal in these transactions as it directs the third party, controls the specified service, performs program utilization review, directs payment to the provider, accepts the financial risk of loss associated with services rendered, and combines the services provided into an integrated solution, as specified within the Company’s customer contracts. The Company has the ability to influence contractual fees with customers and possesses the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, it is required to recognize revenue gross and service partner vendor fees in the operating expense in the Company’s consolidated statements of income. The following table presents revenues disaggregated by service line for the three and six months ended September 30, 2021 and 2020: Three Months Ended Three Months Ended September 30, 2021 September 30, 2020 Patient management services $ 104,669,000 $ 90,250,000 Network solutions services 53,074,000 45,778,000 Total services $ 157,743,000 $ 136,028,000 Six Months Ended Six Months Ended September 30, 2021 September 30, 2020 Patient management services $ 205,118,000 $ 175,471,000 Network solutions services 105,245,000 90,157,000 Total services $ 310,363,000 $ 265,628,000 Arrangements with Multiple Performance Obligations For many of the Company’s services, the Company typically has one performance obligation; however, the Company also provides the customer with an option to acquire additional services. The Company offers multiple services under its patient management and network solutions service lines. The Company typically provides a menu of offerings from which the customer may choose to purchase. The price of each service is separate and distinct and provides a separate and distinct value to the customer. Pricing is generally consistent for each service irrespective of the other services or quantities requested by the customer. Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivables, unbilled receivables, and contract liabilities (reported as deferred revenues) on the Company’s consolidated balance sheets. Unbilled receivables are due to the Company unconditionally for services already rendered except for physical invoicing and the passage of time. Invoicing requirements vary by customer contract, but substantially all unbilled revenues are billed within one year . September 30, 2021 March 31, 2021 Billed receivables $ 52,163,000 $ 50,783,000 Allowance for doubtful accounts ( 2,942,000 ) ( 3,274,000 ) Unbilled receivables 20,217,000 17,213,000 Accounts receivable, net $ 69,438,000 $ 64,722,000 When the Company receives consideration from a customer prior to transferring services to the customer under the terms of certain claims management agreements, it records deferred revenues on the Company’s consolidated balance sheets, which represents a contract liability. Such deferred revenue is included within accrued liabilities on the accompanying consolidated balance sheets. Certain services, such as claims management, are provided under fixed-fee service agreements and require the Company to manage claims over a contract period, typically for one year with the option for auto renewal, with the fixed fee renewing on the anniversary date of such contracts. The Company recognizes deferred revenues as revenues when it performs services and transfers control of the services to the customer and satisfies the performance obligation which it determines utilizing a portfolio approach. For all fixed fee service agreements, revenues are recognized over the expected service periods by type of claim. The table below presents the deferred revenues balance and the significant activity affecting deferred revenues during the six months ended September 30, 2021: Six Months Ended September 30, 2021 Beginning balance at April 1, 2021 $ 22,514,000 Additions 19,370,000 Revenue recognized from beginning of period ( 5,701,000 ) Revenue recognized from additions ( 13,435,000 ) Ending balance at September 30, 2021 $ 22,748,000 Remaining Performance Obligations As of September 30, 2021 , the Company had $ 22.7 million of remaining performance obligations related to claims and non-claims services for which the price is fixed. Remaining performance obligations consist of deferred revenues. The Company expects to recognize approximately 81 % of its remaining performance obligations as revenues within one year and the remaining balance thereafter. See the discussion below regarding the practical expedients elected for the disclosure of remaining performance obligations. Costs to Obtain a Contract The Company has an internal sales force compensation program where remuneration is based solely on the revenues recognized in the period and does not represent an incremental cost to the Company which provides a future benefit expected to be longer than one year and would meet the criteria to be capitalized and presented as unbilled receivables on the Company’s consolidated balance sheets. Practical Expedients Elected As a practical expedient, the Company does not adjust the consideration in a contract for the effects of a significant financing component. It expects, at contract inception, that the period between a customer’s payment of consideration and the transfer of promised services to the customer will be one year or less . For patient management services that are billed on a time-and-expense incurred or per unit basis and for which revenue is recognized over time, the Company recognizes revenue at the amount to which it has the right to invoice for services performed. The Company does not disclose the value of remaining performance obligations for (i) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed, and (ii) contracts with variable consideration allocated entirely to a single performance obligation.

Stock-Based Compensation and St

Stock-Based Compensation and Stock Options	6 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation and Stock Options	Note 3 — Stock-Based Compensation and Stock Options Under the Company’s Restated Omnibus Incentive Plan (formerly the Restated 1988 Executive Stock Option Plan) (“the Plan”) as in effect at September 30, 2021 , options exercisable for up to 20,615,000 shares of the Company’s common stock may be granted over the life of the Plan to key employees, non-employee directors, and consultants at exercise prices not less than the fair market value of the common stock on the date of grant. Options granted under the Plan are non-statutory stock options and generally vest 25 % one year from the date of grant with the remaining 75 % vesting ratably each month for the next 36 months. The options granted to employees and the Company’s Board of Directors expire at the end of five years and ten years from the date of grant, respectively. All options granted in the six months ended September 30, 2021 and 2020 were granted with an exercise price equal to the fair value of the Company’s common stock on the grant date and are non-statutory stock options. The Company records compensation expense for employee stock options based on the estimated fair value of the options on the date of grant using the Black-Scholes option-pricing model with the assumptions included in the table below. The Company uses historical data, among other factors, to estimate the expected volatility, the expected dividend yield and the expected option life. The Company accounts for forfeitures as they occur, rather than estimating expected forfeitures. The risk-free rate is based on the interest rate paid on a U.S. Treasury issue with a term similar to the estimated life of the option. The following assumptions were used to estimate the fair value of options granted during the three months ended September 30, 2021 and 2020 using the Black-Scholes option-pricing model: Three Months Ended September 30, 2021 September 30, 2020 Risk-free interest rate 0.72 % 0.21 % Expected volatility 36 % 34 % Expected dividend yield 0.00 % 0.00 % Expected weighted average life of option in years 4.3 years 4.4 years For the three months ended September 30, 2021 and 2020 , the Company recorded share-based compensation expense of $ 1,355,000 and $ 1,238,000 , respectively. For the six months ended September 30, 2021 and 2020 , the Company recorded share-based compensation expenses of $ 2,701,000 and $ 2,233,000 , respectively. The table below shows the amounts recognized in the unaudited consolidated financial statements for stock compensation expense for time-based options and performance-based options during the three and six mo nths ended September 30, 2021 and 2020, respectively. Three Months Ended September 30, 2021 September 30, 2020 Cost of revenues $ 528,000 $ 506,000 General and administrative 827,000 732,000 Total cost of stock-based compensation included in 1,355,000 1,238,000 Amount of income tax benefit recognized ( 266,000 ) ( 255,000 ) Amount charged against net income $ 1,089,000 $ 983,000 Effect on basic earnings per share $ ( 0.06 ) $ ( 0.05 ) Effect on diluted earnings per share $ ( 0.06 ) $ ( 0.05 ) Six Months Ended September 30, 2021 September 30, 2020 Cost of revenues $ 1,052,000 $ 994,000 General and administrative 1,649,000 1,239,000 Total cost of stock-based compensation included in 2,701,000 2,233,000 Amount of income tax benefit recognized ( 510,000 ) ( 492,000 ) Amount charged against net income $ 2,191,000 $ 1,741,000 Effect on basic earnings per share $ ( 0.12 ) $ ( 0.10 ) Effect on diluted earnings per share $ ( 0.12 ) $ ( 0.10 ) The following table summarizes information for all stock options for the three and six months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 Three Months Ended September 30, 2020 Shares Weighted Shares Weighted Options outstanding, beginning 846,625 $ 68.50 1,017,494 $ 55.54 Options granted 27,250 154.97 41,650 79.49 Options exercised ( 67,915 ) 56.83 ( 80,455 ) 38.66 Options cancelled/forfeited ( 26,978 ) 79.26 ( 2,772 ) 54.70 Options outstanding, ending 778,982 $ 72.17 975,917 $ 57.97 Six Months Ended September 30, 2021 Six Months Ended September 30, 2020 Shares Weighted Shares Weighted Options outstanding, beginning 937,158 $ 64.28 1,029,103 $ 54.87 Options granted 60,250 135.53 86,825 65.55 Options exercised ( 186,671 ) 51.95 ( 124,818 ) 37.77 Options cancelled/forfeited ( 31,755 ) 78.31 ( 15,193 ) 57.09 Options outstanding, ending 778,982 $ 72.17 975,917 $ 57.97 The following table summarizes the status of stock options outstanding and exercisable at September 30, 2021: Range of Exercise Price Number of Weighted Outstanding Exercisable Exercisable $ 22.07 to $ 52.69 195,901 2.64 $ 41.88 160,153 $ 39.64 $ 52.70 to $ 77.93 286,859 2.63 66.65 122,044 62.95 $ 77.94 to $ 88.22 213,272 4.43 86.24 33,377 85.44 $ 88.23 to $ 157.94 82,950 5.37 126.60 — — Total 778,982 3.42 $ 72.17 315,574 $ 53.50 The following table summarizes the status of all outstanding options at September 30, 2021, and changes during the three months then ended: Number Weighted Weighted Aggregate Intrinsic Options outstanding at July 1, 2021 846,625 $ 68.50 Granted 27,250 154.97 Exercised ( 67,915 ) 56.83 Cancelled – forfeited ( 26,823 ) 79.33 Cancelled – expired ( 155 ) 66.77 Ending outstanding 778,982 $ 72.17 3.42 $ 88,845,644 Ending vested and expected to vest 613,980 $ 72.50 3.64 $ 81,650,022 Ending exercisable at September 30, 2021 315,574 $ 53.50 2.76 $ 41,883,649 The weighted-average grant-date fair value of options granted during the three months ended September 30, 2021 and 2020 , was $ 51.88 and $ 22.39 , respectively. Included in the above-noted stock option grants and stock compensation expense are performance-based stock options that vest only upon the Company’s achievement of certain earnings per share targets on a calendar year basis, as determined by the Company’s Board of Directors. These options were valued in the same manner as the time-based options. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options. The Company recognized $ 617,000 and $ 510,000 of stock compensation expense for the three months ended September 30, 2021 and 2020 , respectively, for performance-based stock options.

Treasury Stock

Treasury Stock	6 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Treasury Stock	Note 4 — Treasury Stock The Company’s Board of Directors approved the commencement of a stock repurchase program in the fall of 1996. In May 2021, the Company’s Board of Directors approved a 1,000,000 share expansion to the Company’s existing stock repurchase program, increasing the total number of shares of the Company’s common stock approved for repurchase over the life of the program to 38,000,000 shares. Since the commencement of the stock repurchase program, the Company has spent $ 604 million on the repurchase of 36,937,900 shares of its common stock, equal to 68 % of the outstanding common stock had there been no repurchases. The average price of these repurchases was $ 16.36 per share. These repurchases were funded primarily by the net earnings of the Company, along with proceeds from the exercise of common stock options. During the three and six months ended September 30, 2021, the Company repurchased 165,455 shares of its common stock for $ 25.6 million at an average price of $ 154.48 per share and 284,348 shares of its common stock for $ 39.8 million at an average price of $ 139.81 , respectively. The Company had 17,763,576 shares of common stock outstanding as of September 30, 2021 , net of the 36,937,900 shares in treasury. During the period subsequent to the quarter ended September 30, 2021 , the Company repurchased 49,663 shares of its common stock for $ 8.7 million at an average price of $ 176.02 per share under the Company’s stock repurchase program.

Weighted Average Shares and Net

Weighted Average Shares and Net Income Per Share	6 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Weighted Average Shares and Net Income Per Share	Note 5 — Weighted Average Shares and Net Income Per Share Basic weighted average common shares outstanding decreased to 17,841,000 for the quarter ended September 30, 2021 from 17,937,000 for the quarter ended September 30, 2020 . Diluted weighted average common and common equivalent shares outstanding increased to 18,232,000 for the quarter ended September 30, 2021 from 18,174,000 for the quarter ended September 30, 2020 . Basic weighted average common shares outstanding decreased to 17,869,000 for the six months ended September 30, 2021 from 17,960,000 for the six months ended September 30, 2020 . Diluted weighted average common and common equivalent shares outstanding increased to 18,226,000 for the six months ended September 30, 2021 from 18,144,000 for the six months ended September 30, 2020. Net income per common and common equivalent share was computed by dividing net income by the weighted average number of common and common share equivalents outstanding during the period. The following table sets forth the calculations of the basic and diluted weighted average common shares for the three and six months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 2020 Net Income $ 16,072,000 $ 11,865,000 Basic: Weighted average common shares outstanding 17,841,000 17,937,000 Net Income per share $ 0.90 $ 0.66 Diluted: Weighted average common shares outstanding 17,841,000 17,937,000 Treasury stock impact of stock options 391,000 237,000 Total common and common equivalent shares 18,232,000 18,174,000 Net Income per share $ 0.88 $ 0.65 Six Months Ended September 30, 2021 2020 Net Income $ 32,915,000 $ 20,167,000 Basic: Weighted average common shares outstanding 17,869,000 17,960,000 Net Income per share $ 1.84 $ 1.12 Diluted: Weighted average common shares outstanding 17,869,000 17,960,000 Treasury stock impact of stock options 357,000 184,000 Total common and common equivalent shares 18,226,000 18,144,000 Net Income per share $ 1.81 $ 1.11

Shareholder Rights Plan

Shareholder Rights Plan	6 Months Ended
	Sep. 30, 2021
Text Block [Abstract]
Shareholder Rights Plan	Note 6 — Shareholder Rights Plan During fiscal year 1997, the Company’s Board of Directors approved the adoption of a shareholder rights plan (the “Shareholder Rights Plan”). The Shareholder Rights Plan provides for a dividend distribution to the Company’s shareholders of one preferred stock purchase right for each outstanding share of the Company’s common stock held by such shareholder (as used in this Note, the “right” or the “rights”), only in the event of certain takeover-related events. In November 2008, the Company’s Board of Directors approved an amendment to the Shareholder Rights Plan to extend the expiration date of the rights to February 10, 2022 . The rights are designed to assure that all shareholders receive fair and equal treatment in the event of a proposed takeover of the Company, and to encourage a potential acquirer to negotiate with the Company’s Board of Directors prior to attempting a takeover. The rights are not exercisable until the occurrence of certain takeover-related events, at which time they can be exercised at an exercise price of $ 118 per share of common stock which carries the right, subject to subsequent adjustments. The rights trade with the Company’s common stock. Generally, the Shareholder Rights Plan provides that if a person or group acquires 15 % or more of the Company’s common stock without the approval of the Company’s Board of Directors, subject to certain exceptions, the holders of the rights, other than the acquiring person or group, would, under certain circumstances, have the right to purchase additional shares of the Company’s common stock having a market value equal to two times the then-current exercise price of the right. In addition, if the Company is thereafter merged into another entity, or if 50 % or more of the Company’s consolidated assets or earning power are sold, then the right will entitle its holder to buy common shares of the acquiring entity having a market value equal to two times the then-current exercise price of the right. The Company’s Board of Directors may exchange or redeem the rights under certain conditions.

Contingencies and Legal Proceed

Contingencies and Legal Proceedings	6 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Contingencies and Legal Proceedings	Note 7 — Contingencies and Legal Proceedings The Company is involved in litigation arising in the ordinary course of business. Management believes that resolution of these matters will not result in any payment that, individually or in the aggregate, would be material to the consolidated financial position or results of operations of the Company.

Accounts and Income Taxes Payab

Accounts and Income Taxes Payable and Accrued Liabilities	6 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Accounts and Income Taxes Payable and Accrued Liabilities	Note 8 — Accounts and Income Taxes Payable and Accrued Liabilities The following table sets forth accounts payable, income taxes payable, and accrued liabilities at September 30, 2021 and March 31, 2021: September 30, 2021 March 31, 2021 Accounts payable $ 12,934,000 $ 12,353,000 Income taxes payable and uncertain tax positions 525,000 1,221,000 Total accounts and taxes payable $ 13,459,000 $ 13,574,000 September 30, 2021 March 31, 2021 Payroll, payroll taxes and employee benefits $ 40,644,000 $ 43,998,000 Customer deposits 61,061,000 56,498,000 Accrued professional service fees 6,804,000 7,016,000 Self-insurance accruals 3,247,000 3,704,000 Deferred revenue 22,748,000 22,514,000 Operating lease liabilities 12,446,000 12,765,000 Other 2,239,000 2,391,000 Total accrued liabilities $ 149,189,000 $ 148,886,000

Leases

Leases	6 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	Note 9 — Leases The Company determines if an arrangement is or contains a lease at contract inception. These lease agreements have remaining lease terms of 1 to 15 years . The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the lease commencement date. The lease liability is initially measured at the present value of the unpaid lease payments as of the lease commencement date. Key estimates and judgments include how the Company determines (1) the discount rate it uses to discount the unpaid lease payments to present value, (2) the lease term, and (3) lease payments. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. Generally, the Company cannot determine the interest rate implicit in the lease because it does not have access to the lessor's estimated residual value or the amount of the lessor's deferred initial direct costs. Therefore, the Company generally uses its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Because the Company does not generally borrow on a collateralized basis, it uses quoted interest rates obtained from financial institutions as an input to derive an appropriate incremental borrowing rate, adjusted for the amount of the lease payments, the lease term, and the effect on that rate of designating specific collateral with a value equal to the unpaid lease payments for that lease. The Company’s lease agreements may include options to extend the lease following the initial term. At the time of adopting ASC 842, the Company determined that it was reasonably certain it would exercise the option to renew; accordingly, these options were considered in determining the initial lease term. The Company elected the practical expedient of hindsight in determining the option to renew. The Company has since reassessed the assumption of the renewal term and determined that due to the COVID-19 pandemic, the Company is now expecting more of its workforce to be working from home permanently. Therefore, expecting a reduction in overall square footage of office space needs, the Company no longer believes it is reasonably certain it will exercise most of its options to renew, and therefore, has removed the renewal term of several lease obligations. The subsequent re-measurement reduced the right-of-use asset and related lease liability on the consolidated balance sheet, but had an immaterial impact on the income statement. For lease agreements entered into or reassessed after the adoption of ASC 842, the Company has elected the practical expedient to account for the lease and non-lease components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all of the fixed consideration in the contract. Variable lease payments associated with the Company’s leases are recognized upon occurrence of the event, activity, or circumstance in the lease agreement on which those payments are assessed. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The components of lease expense are as follows: Three Months Ended Three Months Ended September 30, 2021 September 30, 2020 Operating lease expense $ 3,327,000 $ 4,249,000 Finance lease expense 25,000 26,000 Short-term lease expense 3,000 25,000 Variable lease expense 131,000 64,000 Total lease expenses $ 3,486,000 $ 4,364,000 Six Months Ended Six Months Ended September 30, 2021 September 30, 2020 Operating lease expense $ 6,939,000 $ 7,958,000 Finance lease expense 50,000 26,000 Short-term lease expense 7,000 165,000 Variable lease expense 267,000 118,000 Total lease expenses $ 7,263,000 $ 8,267,000 The following table presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets related to its operating leases: September 30, 2021 March 31, 2021 Right-of-use asset, net $ 42,177,000 $ 45,324,000 Short-term lease liability $ 12,446,000 $ 12,765,000 Long-term lease liability 38,458,000 41,898,000 Total lease liabilities $ 50,904,000 $ 54,663,000 Weighted average remaining operating lease term 5.01 years 5.42 years Weighted average remaining finance lease term 3.75 years 4.25 years Weighted average discount rate 2.8 % 3.9 % Supplemental cash flow information related to operating leases for the six months ended September 30, 2021 and 2020 was as follows: Six Months Ended Six Months Ended September 30, 2021 September 30, 2020 Cash paid for amounts included in the measurement of $ 7,557,000 $ 7,352,000 Operating lease liabilities arising from obtaining ROU assets $ 58,752,000 $ 104,108,000 Finance lease liabilities arising from obtaining ROU assets $ 358,000 $ 358,000 Reductions to ROU assets resulting from reductions to $ 3,694,000 $ 928,000 As of September 30, 2021, maturities of operating lease liabilities for each of the next five years and thereafter are as follows: 2022 $ 6,881,000 2023 12,643,000 2024 10,140,000 2025 8,169,000 2026 6,121,000 Thereafter 11,158,000 Total lease payments 55,112,000 Less interest ( 4,208,000 ) Total lease liabilities $ 50,904,000 As of September 30, 2021 , the Company has approximately $ 6.7 million of additional operating lease commitments that have not yet commenced. These additional leases commence in 2021 and have lease terms between 2 years and 7 years.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation: The unaudited consolidated financial statements include the accounts of CorVel Corporation and its subsidiaries. Significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements herein have been prepared by CorVel Corporation (“the Company”, “we”, “our”, “us”) pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The accompanying interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the latest fiscal year ended March 31, 2021. Accordingly, note disclosures which would substantially duplicate the disclosures contained in the March 31, 2021 audited consolidated financial statements have been omitted from these interim unaudited consolidated financial statements. The Company evaluated all subsequent events and transactions through the date of filing this report. Certain information and note disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three and six months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2022. For further information, refer to the audited consolidated financial statements and notes thereto for the fiscal year ended March 31, 2021 included in the Company's Annual Report on Form 10-K filed with the SEC on May 28, 2021
Impact of COVID-19	Impact of COVID-19: T he COVID-19 pandemic has impacted and could further impact our operations and the operations of our customers, suppliers and vendors as a result of quarantines, facility closures, illnesses, reduced medical services, and travel and logistics restrictions. The extent to which the COVID-19 pandemic impacts our business, results of operations, and financial condition will depend on future developments, which are highly uncertain and cannot be predicted. This includes, but is not limited to the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on our customers, suppliers, and vendors, the remedial actions and stimulus measures adopted by federal, state, and local governments, the effects of stay at home mandates, the distribution and effectiveness of vaccines, and to what extent normal economic and operating conditions can resume. Even after the COVID-19 pandemic has subsided, we may continue to experience adverse impacts to our business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, Management cannot reasonably estimate the full impact at this time, however, the Company feels the impact has decreased over time.
Recent Accounting Pronouncements	Recent Accounting Pronouncements: Management has evaluated recent accounting pronouncements through the date the financial statements were issued and filed with the Securities and Exchange Commission and believe that there are none that will have a material impact on the Company’s financial statements.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Sep. 30, 2021
Revenue Recognition [Abstract]
Schedule of Disaggregated Revenue by Service Line	The following table presents revenues disaggregated by service line for the three and six months ended September 30, 2021 and 2020: Three Months Ended Three Months Ended September 30, 2021 September 30, 2020 Patient management services $ 104,669,000 $ 90,250,000 Network solutions services 53,074,000 45,778,000 Total services $ 157,743,000 $ 136,028,000 Six Months Ended Six Months Ended September 30, 2021 September 30, 2020 Patient management services $ 205,118,000 $ 175,471,000 Network solutions services 105,245,000 90,157,000 Total services $ 310,363,000 $ 265,628,000
Schedule of Accounts Receivable, Net	September 30, 2021 March 31, 2021 Billed receivables $ 52,163,000 $ 50,783,000 Allowance for doubtful accounts ( 2,942,000 ) ( 3,274,000 ) Unbilled receivables 20,217,000 17,213,000 Accounts receivable, net $ 69,438,000 $ 64,722,000
Schedule of Deferred Revenues Balance as of Transition Date and Significant Activity Affecting Deferred Revenues	The table below presents the deferred revenues balance and the significant activity affecting deferred revenues during the six months ended September 30, 2021: Six Months Ended September 30, 2021 Beginning balance at April 1, 2021 $ 22,514,000 Additions 19,370,000 Revenue recognized from beginning of period ( 5,701,000 ) Revenue recognized from additions ( 13,435,000 ) Ending balance at September 30, 2021 $ 22,748,000

Stock-Based Compensation and _2

Stock-Based Compensation and Stock Options (Tables)	6 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Fair Value of Options Granted	The following assumptions were used to estimate the fair value of options granted during the three months ended September 30, 2021 and 2020 using the Black-Scholes option-pricing model: Three Months Ended September 30, 2021 September 30, 2020 Risk-free interest rate 0.72 % 0.21 % Expected volatility 36 % 34 % Expected dividend yield 0.00 % 0.00 % Expected weighted average life of option in years 4.3 years 4.4 years
Stock Compensation Expense for Time Based Options and Performance Based Options	The table below shows the amounts recognized in the unaudited consolidated financial statements for stock compensation expense for time-based options and performance-based options during the three and six mo nths ended September 30, 2021 and 2020, respectively. Three Months Ended September 30, 2021 September 30, 2020 Cost of revenues $ 528,000 $ 506,000 General and administrative 827,000 732,000 Total cost of stock-based compensation included in 1,355,000 1,238,000 Amount of income tax benefit recognized ( 266,000 ) ( 255,000 ) Amount charged against net income $ 1,089,000 $ 983,000 Effect on basic earnings per share $ ( 0.06 ) $ ( 0.05 ) Effect on diluted earnings per share $ ( 0.06 ) $ ( 0.05 ) Six Months Ended September 30, 2021 September 30, 2020 Cost of revenues $ 1,052,000 $ 994,000 General and administrative 1,649,000 1,239,000 Total cost of stock-based compensation included in 2,701,000 2,233,000 Amount of income tax benefit recognized ( 510,000 ) ( 492,000 ) Amount charged against net income $ 2,191,000 $ 1,741,000 Effect on basic earnings per share $ ( 0.12 ) $ ( 0.10 ) Effect on diluted earnings per share $ ( 0.12 ) $ ( 0.10 )
Stock Options	The following table summarizes information for all stock options for the three and six months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 Three Months Ended September 30, 2020 Shares Weighted Shares Weighted Options outstanding, beginning 846,625 $ 68.50 1,017,494 $ 55.54 Options granted 27,250 154.97 41,650 79.49 Options exercised ( 67,915 ) 56.83 ( 80,455 ) 38.66 Options cancelled/forfeited ( 26,978 ) 79.26 ( 2,772 ) 54.70 Options outstanding, ending 778,982 $ 72.17 975,917 $ 57.97 Six Months Ended September 30, 2021 Six Months Ended September 30, 2020 Shares Weighted Shares Weighted Options outstanding, beginning 937,158 $ 64.28 1,029,103 $ 54.87 Options granted 60,250 135.53 86,825 65.55 Options exercised ( 186,671 ) 51.95 ( 124,818 ) 37.77 Options cancelled/forfeited ( 31,755 ) 78.31 ( 15,193 ) 57.09 Options outstanding, ending 778,982 $ 72.17 975,917 $ 57.97
Stock Options Outstanding and Exercisable	The following table summarizes the status of stock options outstanding and exercisable at September 30, 2021: Range of Exercise Price Number of Weighted Outstanding Exercisable Exercisable $ 22.07 to $ 52.69 195,901 2.64 $ 41.88 160,153 $ 39.64 $ 52.70 to $ 77.93 286,859 2.63 66.65 122,044 62.95 $ 77.94 to $ 88.22 213,272 4.43 86.24 33,377 85.44 $ 88.23 to $ 157.94 82,950 5.37 126.60 — — Total 778,982 3.42 $ 72.17 315,574 $ 53.50
Outstanding Options	The following table summarizes the status of all outstanding options at September 30, 2021, and changes during the three months then ended: Number Weighted Weighted Aggregate Intrinsic Options outstanding at July 1, 2021 846,625 $ 68.50 Granted 27,250 154.97 Exercised ( 67,915 ) 56.83 Cancelled – forfeited ( 26,823 ) 79.33 Cancelled – expired ( 155 ) 66.77 Ending outstanding 778,982 $ 72.17 3.42 $ 88,845,644 Ending vested and expected to vest 613,980 $ 72.50 3.64 $ 81,650,022 Ending exercisable at September 30, 2021 315,574 $ 53.50 2.76 $ 41,883,649

Weighted Average Shares and N_2

Weighted Average Shares and Net Income Per Share (Tables)	6 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Calculations of Basic and Diluted Weighted Average Common Shares	The following table sets forth the calculations of the basic and diluted weighted average common shares for the three and six months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 2020 Net Income $ 16,072,000 $ 11,865,000 Basic: Weighted average common shares outstanding 17,841,000 17,937,000 Net Income per share $ 0.90 $ 0.66 Diluted: Weighted average common shares outstanding 17,841,000 17,937,000 Treasury stock impact of stock options 391,000 237,000 Total common and common equivalent shares 18,232,000 18,174,000 Net Income per share $ 0.88 $ 0.65 Six Months Ended September 30, 2021 2020 Net Income $ 32,915,000 $ 20,167,000 Basic: Weighted average common shares outstanding 17,869,000 17,960,000 Net Income per share $ 1.84 $ 1.12 Diluted: Weighted average common shares outstanding 17,869,000 17,960,000 Treasury stock impact of stock options 357,000 184,000 Total common and common equivalent shares 18,226,000 18,144,000 Net Income per share $ 1.81 $ 1.11

Accounts and Income Taxes Pay_2

Accounts and Income Taxes Payable and Accrued Liabilities (Tables)	6 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Accounts Payable, Income Taxes Payable and Accrued Liabilities	The following table sets forth accounts payable, income taxes payable, and accrued liabilities at September 30, 2021 and March 31, 2021: September 30, 2021 March 31, 2021 Accounts payable $ 12,934,000 $ 12,353,000 Income taxes payable and uncertain tax positions 525,000 1,221,000 Total accounts and taxes payable $ 13,459,000 $ 13,574,000 September 30, 2021 March 31, 2021 Payroll, payroll taxes and employee benefits $ 40,644,000 $ 43,998,000 Customer deposits 61,061,000 56,498,000 Accrued professional service fees 6,804,000 7,016,000 Self-insurance accruals 3,247,000 3,704,000 Deferred revenue 22,748,000 22,514,000 Operating lease liabilities 12,446,000 12,765,000 Other 2,239,000 2,391,000 Total accrued liabilities $ 149,189,000 $ 148,886,000

Leases (Tables)

Leases (Tables)	6 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Summary of Components of Lease Expenses	The components of lease expense are as follows: Three Months Ended Three Months Ended September 30, 2021 September 30, 2020 Operating lease expense $ 3,327,000 $ 4,249,000 Finance lease expense 25,000 26,000 Short-term lease expense 3,000 25,000 Variable lease expense 131,000 64,000 Total lease expenses $ 3,486,000 $ 4,364,000 Six Months Ended Six Months Ended September 30, 2021 September 30, 2020 Operating lease expense $ 6,939,000 $ 7,958,000 Finance lease expense 50,000 26,000 Short-term lease expense 7,000 165,000 Variable lease expense 267,000 118,000 Total lease expenses $ 7,263,000 $ 8,267,000
Summary of Lease Related Assets and Liabilities Recorded in Balance Sheet Related to Operating Leases	The following table presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets related to its operating leases: September 30, 2021 March 31, 2021 Right-of-use asset, net $ 42,177,000 $ 45,324,000 Short-term lease liability $ 12,446,000 $ 12,765,000 Long-term lease liability 38,458,000 41,898,000 Total lease liabilities $ 50,904,000 $ 54,663,000 Weighted average remaining operating lease term 5.01 years 5.42 years Weighted average remaining finance lease term 3.75 years 4.25 years Weighted average discount rate 2.8 % 3.9 %
Schedule of Supplemental Cash Flow Information Related to Operating Leases	Supplemental cash flow information related to operating leases for the six months ended September 30, 2021 and 2020 was as follows: Six Months Ended Six Months Ended September 30, 2021 September 30, 2020 Cash paid for amounts included in the measurement of $ 7,557,000 $ 7,352,000 Operating lease liabilities arising from obtaining ROU assets $ 58,752,000 $ 104,108,000 Finance lease liabilities arising from obtaining ROU assets $ 358,000 $ 358,000 Reductions to ROU assets resulting from reductions to $ 3,694,000 $ 928,000
Summary of Maturities of Operating Lease Liabilities	As of September 30, 2021, maturities of operating lease liabilities for each of the next five years and thereafter are as follows: 2022 $ 6,881,000 2023 12,643,000 2024 10,140,000 2025 8,169,000 2026 6,121,000 Thereafter 11,158,000 Total lease payments 55,112,000 Less interest ( 4,208,000 ) Total lease liabilities $ 50,904,000

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) $ in Millions	6 Months Ended
	Sep. 30, 2021USD ($)Segment
Disaggregation Of Revenue [Line Items]
Accounts receivable due period	30 days
Number of reportable segments | Segment	1
Revenue recognition, number of performance obligation	1
Latest duration of unbilled revenue, billing	1 year
Revenue, remaining performance obligation, amount | $	$ 22.7
Revenue, remaining performance obligation, percentage	81.00%
Revenue, remaining performance obligation, expected timing of satisfaction, explanation	The Company expects to recognize approximately 81% of its remaining performance obligations as revenues within one year and the remaining balance thereafter.
Capitalized contract cost, judgment	The Company has an internal sales force compensation program where remuneration is based solely on the revenues recognized in the period and does not represent an incremental cost to the Company which provides a future benefit expected to be longer than one year and would meet the criteria to be capitalized and presented as unbilled receivables on the Company’s consolidated balance sheets.
Period between consideration received and service rendered	one year or less
Patient Management Services [Member]
Disaggregation Of Revenue [Line Items]
Contract with customer, performance obligation, description	The Company’s obligation to manage claims and cases under the patient management service line can range from less than one year to multi-year contracts. They are generally one year under the terms of the contract; however, many of these contracts contain auto-renewal provisions and the Company’s customer relationships can span multiple years. Under certain claims management agreements, the Company receives consideration from a customer at contract inception prior to transferring services to the customer, however, the Company would begin performing services immediately. The period between a customer’s payment of consideration and the completion of the promised services is generally less than one year. There is no difference between the amount of promised consideration and the cash selling price of the promised services. The fee is billed upfront by the Company in order to provide customers with simplified and predictable ways of purchasing the Company’s services.
Patient Management Services [Member] | Minimum [Member]
Disaggregation Of Revenue [Line Items]
Revenue recognition, time elapsed for claims	3 months
Patient Management Services [Member] | Maximum [Member]
Disaggregation Of Revenue [Line Items]
Revenue recognition, time elapsed for claims	15 months

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Revenues Disaggregated by Service Line (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation Of Revenue [Line Items]
Total services	$ 157,743,000	$ 136,028,000	$ 310,363,000	$ 265,628,000
Patient Management Services [Member]
Disaggregation Of Revenue [Line Items]
Total services	104,669,000	90,250,000	205,118,000	175,471,000
Network Solutions Services [Member]
Disaggregation Of Revenue [Line Items]
Total services	$ 53,074,000	$ 45,778,000	$ 105,245,000	$ 90,157,000

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of Accounts Receivable, Net (Detail) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Accounts Receivable Net Current [Abstract]
Billed receivables	$ 52,163,000	$ 50,783,000
Allowance for doubtful accounts	(2,942,000)	(3,274,000)
Unbilled receivables	20,217,000	17,213,000
Accounts receivable, net	$ 69,438,000	$ 64,722,000

Revenue Recognition - Schedul_3

Revenue Recognition - Schedule of Deferred Revenues Balance as of Transition Date and Significant Activity Affecting Deferred Revenues (Detail)	6 Months Ended
	Sep. 30, 2021USD ($)
Change In Contract With Customer Liability [Abstract]
Beginning balance at April 1, 2021	$ 22,514,000
Additions	19,370,000
Revenue recognized from beginning of period	(5,701,000)
Revenue recognized from additions	(13,435,000)
Ending balance at September 30, 2021	$ 22,748,000

Revenue Recognition - Additio_2

Revenue Recognition - Additional Information (Detail1)	Sep. 30, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-10-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation, expected recognition as revenue, period	1 year

Stock-Based Compensation and _3

Stock-Based Compensation and Stock Options - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-statutory stock options expiration period			5 years
Weighted-average grant-date fair value of options granted	$ 51.88	$ 22.39
Time Based Options and Performance Based Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,355,000	$ 1,238,000	$ 2,701,000	$ 2,233,000
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 617,000	$ 510,000
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-statutory stock options expiration period			10 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock grants	20,615,000		20,615,000
Non-statutory stock options vesting period			36 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-statutory stock options vesting period			1 year
Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting Percentage			25.00%
Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting Percentage			75.00%

Stock-Based Compensation and _4

Stock-Based Compensation and Stock Options - Fair Value of Options Granted (Detail)	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rate	0.72%	0.21%
Expected volatility	36.00%	34.00%
Expected dividend yield	0.00%	0.00%
Expected weighted average life of option in years	4 years 3 months 18 days	4 years 4 months 24 days

Stock-Based Compensation and _5

Stock-Based Compensation and Stock Options - Stock Compensation Expense for Time Based Options and Performance Based Options (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Effect on basic earnings per share	$ 0.90	$ 0.66	$ 1.84	$ 1.12
Effect on diluted earnings per share	$ 0.88	$ 0.65	$ 1.81	$ 1.11
Time Based Options and Performance Based Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total cost of stock-based compensation included in income before income tax provision	$ 1,355,000	$ 1,238,000	$ 2,701,000	$ 2,233,000
Amount of income tax benefit recognized	(266,000)	(255,000)	(510,000)	(492,000)
Amount charged against net income	$ 1,089,000	$ 983,000	$ 2,191,000	$ 1,741,000
Effect on basic earnings per share	$ (0.06)	$ (0.05)	$ (0.12)	$ (0.10)
Effect on diluted earnings per share	$ (0.06)	$ (0.05)	$ (0.12)	$ (0.10)
Time Based Options and Performance Based Options [Member] | Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total cost of stock-based compensation included in income before income tax provision	$ 528,000	$ 506,000	$ 1,052,000	$ 994,000
Time Based Options and Performance Based Options [Member] | General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total cost of stock-based compensation included in income before income tax provision	$ 827,000	$ 732,000	$ 1,649,000	$ 1,239,000

Stock-Based Compensation and _6

Stock-Based Compensation and Stock Options - Stock Options (Detail) - $ / shares	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, beginning balance, Shares	846,625	1,017,494	937,158	1,029,103
Options granted, Shares	27,250	41,650	60,250	86,825
Options exercised, Shares	(67,915)	(80,455)	(186,671)	(124,818)
Options cancelled/forfeited, Shares	(26,978)	(2,772)	(31,755)	(15,193)
Options outstanding, ending balance, Shares	778,982	975,917	778,982	975,917
Options outstanding, beginning balance, Weighted Average Exercise Price	$ 68.50	$ 55.54	$ 64.28	$ 54.87
Options granted, Weighted Average Exercise Price	154.97	79.49	135.53	65.55
Options exercised, Weighted Average Exercise Price	56.83	38.66	51.95	37.77
Options cancelled/forfeited, Weighted Average Exercise Price	79.26	54.70	78.31	57.09
Options outstanding, ending balance, Weighted Average Exercise Price	$ 72.17	$ 57.97	$ 72.17	$ 57.97

Stock-Based Compensation and _7

Stock-Based Compensation and Stock Options - Stock Options Outstanding and Exercisable (Detail) - $ / shares	6 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Outstanding Options	778,982	846,625	937,158	975,917	1,017,494	1,029,103
Weighted Average Remaining Contractual Life	3 years 5 months 1 day
Outstanding Options – Weighted Average Exercise Price	$ 72.17	$ 68.50	$ 64.28	$ 57.97	$ 55.54	$ 54.87
Exercisable Options – Number of Exercisable Options	315,574
Exercisable Options – Weighted Average Exercise Price	$ 53.50
Range of Exercise Price, $22.07 to $52.69 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, lower limit	22.07
Range of Exercise Price, upper limit	$ 52.69
Number of Outstanding Options	195,901
Weighted Average Remaining Contractual Life	2 years 7 months 20 days
Outstanding Options – Weighted Average Exercise Price	$ 41.88
Exercisable Options – Number of Exercisable Options	160,153
Exercisable Options – Weighted Average Exercise Price	$ 39.64
Range of Exercise Price, $52.70 to $70.24 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, lower limit	52.70
Range of Exercise Price, upper limit	$ 77.93
Number of Outstanding Options	286,859
Weighted Average Remaining Contractual Life	2 years 7 months 17 days
Outstanding Options – Weighted Average Exercise Price	$ 66.65
Exercisable Options – Number of Exercisable Options	122,044
Exercisable Options – Weighted Average Exercise Price	$ 62.95
Range of Exercise Price, $70.25 to $87.69 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, lower limit	77.94
Range of Exercise Price, upper limit	$ 88.22
Number of Outstanding Options	213,272
Weighted Average Remaining Contractual Life	4 years 5 months 4 days
Outstanding Options – Weighted Average Exercise Price	$ 86.24
Exercisable Options – Number of Exercisable Options	33,377
Exercisable Options – Weighted Average Exercise Price	$ 85.44
Range of Exercise Price, $87.70 to $119.48 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, lower limit	88.23
Range of Exercise Price, upper limit	$ 157.94
Number of Outstanding Options	82,950
Weighted Average Remaining Contractual Life	5 years 4 months 13 days
Outstanding Options – Weighted Average Exercise Price	$ 126.60
Exercisable Options – Number of Exercisable Options	0
Exercisable Options – Weighted Average Exercise Price	$ 0

Stock-Based Compensation and _8

Stock-Based Compensation and Stock Options - Outstanding Options (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, beginning balance, Shares	846,625	1,017,494	937,158	1,029,103
Granted, Number of Options	27,250	41,650	60,250	86,825
Exercised, Number of Options	(67,915)	(80,455)	(186,671)	(124,818)
Cancelled - forfeited, Number of Options	(26,823)
Cancelled - expired, Number of Options	(155)
Options outstanding, ending balance, Shares	778,982	975,917	778,982	975,917
Ending vested and expected to vest, Number of Options	613,980		613,980
Ending exercisable, Number of Options	315,574		315,574
Options outstanding, beginning balance, Weighted Average Exercise Price	$ 68.50	$ 55.54	$ 64.28	$ 54.87
Granted, Weighted Average Exercise Price per Share	154.97	79.49	135.53	65.55
Exercised, Weighted Average Exercise Price per Share	56.83	38.66	51.95	37.77
Cancelled - forfeited, Weighted Average Exercise Price per Share	79.33
Cancelled - expired, Weighted Average Exercise Price per Share	66.77
Options outstanding, ending balance, Weighted Average Exercise Price	72.17	$ 57.97	72.17	$ 57.97
Ending vested and expected to vest, Weighted Average Exercise Price per Share	72.50		72.50
Ending exercisable, Weighted Average Exercise Price per Share	$ 53.50		$ 53.50
Option outstanding, Weighted Average Remaining Contractual Life (Years)	3 years 5 months 1 day
Ending vested and expected to vest, Weighted Average Remaining Contractual Life (Years)	3 years 7 months 20 days
Ending exercisable, Weighted Average Remaining Contractual Life (Years)	2 years 9 months 3 days
Ending Outstanding Aggregate Intrinsic Value	$ 88,845,644		$ 88,845,644
Ending vested and expected to vest, Aggregate Intrinsic Value	81,650,022		81,650,022
Ending exercisable, Aggregate Intrinsic Value	$ 41,883,649		$ 41,883,649

Treasury Stock - Additional Inf

Treasury Stock - Additional Information (Detail) - USD ($)	Oct. 01, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	May 30, 2021	Mar. 31, 2021
Class of Stock [Line Items]
Number of shares of common stock authorized to repurchase		38,000,000		38,000,000		1,000,000
Treasury stock, value		$ 604,190,000		$ 604,190,000			$ 564,435,000
Treasury stock, shares		36,937,900		36,937,900			36,653,552
Average price per share of common stock		$ 154.48		$ 139.81
Common stock, shares outstanding		17,763,576		17,763,576			17,876,090
Number of shares of common stock repurchased		165,455		284,348
Treasury stock, value, acquired, cost method		$ 25,559,000	$ 12,042,000	$ 39,755,000	$ 14,440,000
TreasuryStock, Shares Outstanding		36,937,900		36,937,900
Nineteen Ninety Six Share Repurchase Program [Member]
Class of Stock [Line Items]
Common stock equals to percentage of outstanding common stock				68.00%
Average price per share of common stock				$ 16.36
Subsequent Event [Member]
Class of Stock [Line Items]
Average price per share of common stock	$ 176.02
Number of shares of common stock repurchased	49,663
Treasury stock, value, acquired, cost method	$ 8,700,000

Weighted Average Shares and N_3

Weighted Average Shares and Net Income Per Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Basic weighted average common shares outstanding	17,841,000	17,937,000	17,869,000	17,960,000
Diluted weighted average common and common equivalent shares outstanding	18,232,000	18,174,000	18,226,000	18,144,000

Weighted Average Shares and N_4

Weighted Average Shares and Net Income Per Share - Calculations of Basic and Diluted Weighted Average Common Shares (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Income	$ 16,072,000	$ 11,865,000	$ 32,915,000	$ 20,167,000
Basic:
Basic weighted average common shares outstanding	17,841,000	17,937,000	17,869,000	17,960,000
Basic	$ 0.90	$ 0.66	$ 1.84	$ 1.12
Diluted:
Weighted Average Number Of Shares Outstanding Basic	17,841,000	17,937,000	17,869,000	17,960,000
Treasury stock impact of stock options	391,000	237,000	357,000	184,000
Total common and common equivalent shares	18,232,000	18,174,000	18,226,000	18,144,000
Diluted	$ 0.88	$ 0.65	$ 1.81	$ 1.11

Shareholder Rights Plan - Addit

Shareholder Rights Plan - Additional Information (Detail) - $ / shares	1 Months Ended	6 Months Ended
	Nov. 30, 2008	Sep. 30, 2021
Equity [Abstract]
Dividend distribution ratio of preferred share purchase right for outstanding share of common stock		100.00%
Shareholder rights expiration date	Feb. 10, 2022
Shareholder rights exercise price		$ 118
Shareholder Rights Plan, description of acquired entity		Shareholder Rights Plan provides that if a person or group acquires 15% or more of the Company’s common stock
Shareholder Rights Plan, percentage of acquired entity		15.00%
Shareholder Rights Plan, description of merged entity		Company is thereafter merged into another entity, or if 50% or more of the Company’s consolidated assets or earning power are sold, then the right will entitle its holder to buy common shares of the acquiring entity having a market value equal to two times the then-current exercise price of the right.
Shareholder Rights Plan, percentage of merged entity		50.00%

Accounts and Income Taxes Pay_3

Accounts and Income Taxes Payable and Accrued Liabilities - Accounts Payable and Income Taxes Payable (Detail) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Payables And Accruals [Abstract]
Accounts payable	$ 12,934,000	$ 12,353,000
Income taxes payable and uncertain tax positions	525,000	1,221,000
Total accounts and taxes payable	$ 13,459,000	$ 13,574,000

Accounts and Income Taxes Pay_4

Accounts and Income Taxes Payable and Accrued Liabilities - Accrued Liabilities (Detail) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Payables And Accruals [Abstract]
Payroll, payroll taxes and employee benefits	$ 40,644,000	$ 43,998,000
Customer deposits	61,061,000	56,498,000
Accrued professional service fees	6,804,000	7,016,000
Self-insurance accruals	3,247,000	3,704,000
Deferred revenue	22,748,000	22,514,000
Operating lease liabilities	12,446,000	12,765,000
Other	2,239,000	2,391,000
Total accrued liabilities	$ 149,189,000	$ 148,886,000

Leases - Additional Information

Leases - Additional Information (Detail) $ in Millions	6 Months Ended
	Sep. 30, 2021USD ($)
Lessee Lease Description [Line Items]
Additional operating lease commitments not yet commenced	$ 6.7
Minimum [Member]
Lessee Lease Description [Line Items]
Remaining lease term	1 year
Operating lease commitments not yet commenced, lease term	2 years
Maximum [Member]
Lessee Lease Description [Line Items]
Remaining lease term	15 years
Operating lease commitments not yet commenced, lease term	7 years

Leases - Summary of Components

Leases - Summary of Components of Lease Expenses (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Operating lease expense	$ 3,327,000	$ 4,249,000	$ 6,939,000	$ 7,958,000
Finance lease expense	25,000	26,000	50,000	26,000
Short-term lease expense	3,000	25,000	7,000	165,000
Variable lease expense	131,000	64,000	267,000	118,000
Total lease expenses	$ 3,486,000	$ 4,364,000	$ 7,263,000	$ 8,267,000

Leases - Summary of Lease Relat

Leases - Summary of Lease Related Assets and Liabilities Recorded in Balance Sheet Related to Operating Leases (Details) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Lessee Lease Description [Line Items]
Right-of-use asset, net	$ 42,177,000	$ 45,324,000
Long-term lease liability	38,458,000	41,898,000
Total lease liabilities	$ 50,904,000	$ 54,663,000
Weighted average remaining operating lease term	5 years 3 days	5 years 5 months 1 day
Weighted average remaining finance lease term	3 years 9 months	4 years 3 months
Weighted average discount rate	2.80%	3.90%
Accrued Liabilities [Member]
Lessee Lease Description [Line Items]
Short-term lease liability	$ 12,446,000	$ 12,765,000

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Detail) - USD ($)	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 7,557,000	$ 7,352,000
Operating lease liabilities arising from obtaining ROU assets	58,752,000	104,108,000
Finance lease liabilities arising from obtaining ROU assets	358,000	358,000
Reductions to ROU assets resulting from reductions to operating lease liabilities	$ 3,694,000	$ 928,000

Leases - Summary of Maturities

Leases - Summary of Maturities of Operating Lease Liabilities (Details) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Operating Lease Liabilities Payments Due [Abstract]
2022	$ 6,881,000
2023	12,643,000
2024	10,140,000
2025	8,169,000
2026	6,121,000
Thereafter	11,158,000
Total lease payments	55,112,000
Less interest	(4,208,000)
Total lease liabilities	$ 50,904,000	$ 54,663,000